Drug-metabolizing enzymes (DMEs) have shown increasing importance in anticancer therapy. It is not only due to their effect on activation or deactivation of anticancer drugs, but also because of their extensive connections with pathological and biochemistry changes during tumorigenesis. Meanwhile, it has become more accessible to discovery anticancer drugs that selectively targeted cancer cells with the development of synthetic lethal screen technology. Synthetic lethal strategy makes use of unique genetic markers that different cancer cells from normal tissues to discovery anticancer agents. Dysregulation of DMEs has been found in various cancers, making them promising candidates for synthetic lethal strategy. In this review, we will systematically discuss about the role of DMEs in tumor progression, the application of synthetic lethality strategy in drug discovery, and a link between DMEs and synthetic lethal of cancer.

药物代谢酶 (DME) 在抗癌治疗中的重要性日益增加。这不仅是因为它们对抗癌药物的激活或失活有影响，还因为它们与肿瘤发生过程中的病理和生化变化有着广泛的联系。同时，随着合成致死筛选技术的发展，更容易发现选择性靶向癌细胞的抗癌药物。合成致死策略利用独特的遗传标记将癌细胞与正常组织区分开来以发现抗癌剂。在多种癌症中发现了 DME 的失调，这使它们成为合成致死策略的有希望的候选者。在这篇综述中，我们将系统地讨论 DME 在肿瘤进展中的作用，